Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zealand Pharma begins dosing in Phase III trial for CHI

CHI is a rare paediatric disease caused due to a genetic defect in the insulin producing cells. Credit: Pexels via Pixabay.



  • Zealand Pharma begins dosing in Phase III trial for CHI

Go Top